Michał Wieliński
Managing Associate
Attorney-at-law
Languages:
Joined GESSEL in 2021. His main area of expertise is capital market law. Michał advises on mergers and acquisitions and corporate disputes. He handles transactions related to raising equity and debt financing through issue of financial instruments. Advises on flotations on the Warsaw Stock Exchange and the NewConnect market. Handles transactions of primary and secondary public offerings (IPOs, SPOs), accelerated book-building processes (ABB), public M&A, tender offers for sale of shares in public companies, delisting, squeeze-outs and buy-backs. Works for issuers, financial institutions, sellers and investors. Also advises on M&A transactions, supporting buyers, sellers and management of acquired companies.
Represents clients in proceedings before the Financial Supervision Authority, the Warsaw Stock Exchange board, and the National Depository for Securities. Advises on admission of financial instruments to public trading and their dematerialization.
Supports clients in significant corporate matters, including reorganization processes and the structuring and implementation of incentive programs. Attends meetings of corporate bodies. Serves as chairman of general meetings of public companies. Advises on the implementation of disclosure obligations.
Experience
Latest projects
- Advised Pure Biologics on the acquisition of US-based Dystrogen Gene Therapies from the private capital fund BioFund Capital Management LLC and JD Copilot LLC through a share exchange, the conversion into shares of debt owed to private investment firm ACRX Investments Limited, and a public offering of shares, with an aggregate issue price of PLN 213.5 million
- Advised the founders of Clicktrans, a leading European online transport platform, on the sale of a 70% stake to private equity fund Spire Capital Partners, with the founders retaining significant minority stakes
- Advised Creotech Instruments, a WSE-listed company, on a public offering of newly issued Series M shares conducted through an accelerated bookbuilding process (ABB), valued at PLN 481 million, and their admission to trading on the WSE
- Advised WSE-listed technology company cyber_Folks on the sale of a 19.53% stake in Vercom, a global CPaaS provider, through an accelerated bookbuilding process for PLN 520.8 million, while remaining Vercom’s largest shareholder
- Advised Creotech Instruments on the spin-off of its quantum business and the WSE listing of Creotech Quantum, with an equity value of approximately PLN 535.6 million
Education and achievements
- Legal studies at the Faculty of Law and Administration of Adam Mickiewicz University in Poznań; Studies in international relations (international business and world economy at Adam Mickiewicz University in Poznań (2011)
- British Law School organized by the British Law Centre (2012), study at Universiteit Gent in Belgium (Erasmus program, 2014)
Awards
Academic publications
News
& Insights
03.09.2026
GESSEL advised cyber_Folks and Shoper on merger creating a near USD 1 billion listed technology group
GESSEL acted as joint legal counsel to cyber_Folks S.A., a European leader in e-commerce technology, and Shoper S.A., Poland’s most frequently chosen online store platfo...
05.08.2026
GESSEL advised Pure Biologics on a multi-stage transaction comprising a share exchange offer, debt-to-equity conversion and public share offering
GESSEL advised Pure Biologics S.A., a biopharmaceutical company listed on the Warsaw Stock Exchange, on a complex, multi-stage and multi-jurisdictional transaction combi...
29.07.2026
GESSEL advised the founders of Clicktrans on the sale of a majority stake to Spire Capital
GESSEL advised Agnieszka Korzeniewska and Michał Brzeziński, the founders of Clicktrans sp. z o.o., one of Europe's largest online marketplaces connecting customers with...
14.07.2026
GESSEL advised Creotech Instruments on a PLN 481 million public offering
GESSEL advised Creotech Instruments S.A., a Warsaw Stock Exchange listed space technology company, in connection with its public offering of 650,000 Series M shares cond...
